Skip to main content
. 2023 Nov 21;42:100953. doi: 10.1016/j.lanwpc.2023.100953

Fig. 3.

Fig. 3

Anti-spike IgG and SARS-CoV RBD–hACE2 inhibition (%) against Wuhan-Hu-1 and B.1.1.529 variants at Day-0 and Day-28 visits, by study arm and priming strata. Horizontal black lines with vertical bars indicate the median and 25th–75th percentiles. GMR: Geometric mean ratio in Day-28 levels between fractional and standard dose arms, adjusted for age group, priming vaccine, duration between first and second dose, duration between second and third (study) dose, study day of blood draw, and baseline anti-spike IgG.